Biogen ProblemsYou'll recall that I have argued against the probability of a deal being done between Bioasis and Bioasis for the delivery of aducanumab across the BBB. My contention is that drug likely isn't good enough and that the 5 years it would take to move an xB3-aducanumab drug through clinical trials is so long that other approaches to Alzheimer's would probably be more efficacious. In other words, Biogen is unlikely to invest further in aducanumab except to get approval of it and some revenue from it before it dies on the vine.
Endpoints News John Carroll today reported on a scathing analysis of Biogen and aducanumab by Brian P. Skorney, CFA, a Baird's Biotech Senior Research Analyst. Skorney's analysis has been widely reported, including by John Carroll at Endpoints News.
I urge you to read the Endpoints' article, entitled, "
Analyst Brian Skorney goes grizzly on Biogen’s Alzheimer’s ‘hype,’ ‘fearmongering’ and ‘statistical malpractice'." The Baird analysis has resulted in a Biogen market cap decline today of almost $1.5 billion or 2.7%.
As much as all of us would like to see a deal with Biogen or any other big pharma, I don't believe in throwing names around just to pump the stock. Predictions about BD opportunities require research to be credible.
Further, Bioasis is already in talks (negotiations? maybe? likely?) with a number of pharmas, large and small. We also have an impressive development pipeline, backed up by strong IP protection. I'm not suggesting that Bioasis should or will turn down negotiations with anybody, but neither can Bioasis run madly about in all directions chasing every unresearched recommendation from Stockhouse posters. Bioasis is already busy doing what we need them to do. Let's just let them get that done.
jdstox